Reneo Pharmaceuticals, Inc. (RPHM)
NASDAQ: RPHM · IEX Real-Time Price · USD
1.675
-0.015 (-0.89%)
At close: Apr 23, 2024, 4:00 PM
1.650
-0.025 (-1.49%)
After-hours: Apr 23, 2024, 5:30 PM EDT
Company Description
Reneo Pharmaceuticals, Inc., a clinical-stage pharmaceutical company, focuses on the development and commercialization of therapies for patients with rare genetic mitochondrial diseases.
The company's lead product candidate is REN001, a potent and selective agonist of the peroxisome proliferator-activated receptor delta that is in clinical development for genetic mitochondrial diseases comprising primary mitochondrial myopathies and long-chain fatty acid oxidation disorders.
Reneo Pharmaceuticals, Inc. was incorporated in 2014 and is headquartered in Irvine, California.
Reneo Pharmaceuticals, Inc.
Country | United States |
Founded | 2014 |
IPO Date | Apr 9, 2021 |
Industry | Biotechnology |
Sector | Healthcare |
Employees | 8 |
CEO | Gregory J. Flesher |
Contact Details
Address: 18575 Jamboree Road, Suite 275-s Irvine, California 92612 United States | |
Phone | (858) 283-0280 |
Website | reneopharma.com |
Stock Details
Ticker Symbol | RPHM |
Exchange | NASDAQ |
Fiscal Year | January - December |
Reporting Currency | USD |
IPO Price | $15.00 |
CIK Code | 0001637715 |
CUSIP Number | 75974E103 |
ISIN Number | US75974E1038 |
Employer ID | 47-2309515 |
SIC Code | 2834 |
Key Executives
Name | Position |
---|---|
Michael G. Grey | Founder and Executive Chairman |
Gregory J. Flesher | President, Chief Executive Officer and Director |
Michael P. Cruse | Chief Operating Officer |
Ashley F. Hall J.D. | Chief Development Officer |
Jennifer P. Lam | SVice President of Finance and Administration and Principal Financial & Accounting Officer |
Dr. Alejandro Dorenbaum M.D. | Chief Medical Officer |
Lynn Purkins Ph.D. | Senior Vice President of Global Development |
Latest SEC Filings
Date | Type | Title |
---|---|---|
Mar 28, 2024 | S-8 | Securities to be offered to employees in employee benefit plans |
Mar 28, 2024 | 10-K | Annual Report |
Mar 28, 2024 | 8-K | Current Report |
Feb 23, 2024 | 8-K | Current Report |
Feb 5, 2024 | SC 13G | Statement of acquisition of beneficial ownership by individuals |
Jan 17, 2024 | SC 13G | Statement of acquisition of beneficial ownership by individuals |
Dec 26, 2023 | SC 13D | General statement of acquisition of beneficial ownership |
Dec 15, 2023 | SC 13D/A | [Amend] General statement of acquisition of beneficial ownership |
Dec 14, 2023 | 8-K | Current Report |
Nov 21, 2023 | EFFECT | Notice of Effectiveness |